13997760 l
Kantum 20bio logo cmyk

KANTUM DIAGNOSTICS INC (DBA KANTUM BIO)

SAVING LIVES THROUGH EARLY DETECTION AND TREATMENT OF ACUTE KIDNEY INJURY

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Concord, NH, US
  • Currency USD
  • Founded April 2016
  • Employees 0
  • Incorporation Type C-corp
  • Website kantumdx.com

Company Summary

Acute Kidney Injury (AKI) affects over 4 million people each year in the US, and costs more than $10 billion. Kantum Bio has identified UDP-glucose (UDP-G) as an early biomarker for AKI. UDP-G outperforms any other AKI biomarkers. Kantum Bio has also identified a molecule that can be developed into a new drug for AKI. The annual market opportunity for AKI diagnostics and therapy represents several billions of dollars worldwide.

Team

  • Jean-Francois is CEO and Founder of Kantum Research, a firm specialized in building strategic insight and innovation in marketing research. He is former Senior VP and lead researcher at RBS Citizens Bank. Jean-Francois is a marketing professional with over 30 years of experience conducting qualitative and quantitative market research studies. In 2008, he launched Business Scientifics, a multi-million dollar market intelligence research company.

  • F0ee3ec8 3a12 4cc1 a17c 348276b20051
    Chief Scientific Officer

    Dr. Breton is Professor of Medicine at Harvard Medical School, and directs the Breton Laboratory within the Program in Membrane Biology/Center for Systems Biology in the Nephrology Division at the Massachusetts General Hospital. She is a board member of the American Journal of Physiology: Renal Physiology. She has published over 100 papers since 1993. Prof. Breton is the recipient of several research awards.

  • Default avatar
    Patrick Yeramian
    Chief Medical Officer

    Expert in clinical drug development from pre-IND to registration. Since 1987, Dr. Yeramian has held roles from Medical Director to Chief Medical Officer in both academic and industry sectors in Europe and the US (including Searle, Viragen, Transmolecular, Swedish Orphan Biovitrum, and Soligenix). He supervised several project teams to file over 20 INDs and 5 NDA/sNDAs,
    and conducted large international Phase III trials in the US and the EU.

  • 3e86af77 08a6 4f74 82b4 5cd92f9b9062
    Chief Business Officer

    Healthcare and life sciences business professional. David Giddings started his career at Eastman Kodak and joined Boehringer Mannheim in 1991 as VP and General Manager of its Diagnostics Division, and subsequently became President and COO of the company. He was appointed Chairman, President, and CEO of Diametrics Medical in 1995, a NASDAQ company, where he served for 6 years. Mr. Giddings served as Digilab Inc’s President & CEO until July, 2009.

  • Trained and practiced as a scientist, and later schooled on-the-job as a health economist, marketer and drug developer, John Randle brings over 30 years of hands-on experience to the business of pharmaceutical discovery & development from target and lead selection through clinical proof of concept, notably at Vertex Pharmaceuticals, Servier and Rhône-Poulenc Rorer and Annovation Biopharma.